FINWIRES · TerminalLIVE
FINWIRES

$VERA

7 stories mentioning VERAUpdated 30d ago

Every FINWIRES story that references VERA, newest first.

Sectors

Sector Update: Healthcare Stocks Gain Late Afternoon

Healthcare stocks were higher late Tuesday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each adding 1.4%.The iShares Biotechnology ETF (IBB) climbed 1.4%.In corporate news, Vertex Pharmaceuticals (VRTX) agreed to buy endocrine disease drugmaker Crinetics Pharmaceuticals (CRNX) for a total equity value of about $10 billion. Crinetics shares jumped 98%, and Vertex was down 1.2%.Eli Lilly (LLY) Canada said Tuesday that Health Canada has approved Mounjaro for pediatric patients aged 10 to 17 with type 2 diabetes. Lilly shares rose 2.7%.Vera Therapeutics' (VERA) Trutakna has been approved to reduce proteinuria in adults with primary immunoglobulin A nephropathy, the US Food and Drug Administration said in a Tuesday statement. Vera Therapeutics shares jumped by more than 7%.AstraZeneca (AZN) has signed an agreement to access Helix's genomic datasets to support research for drug discovery and development, Helix said Tuesday. AstraZeneca shares added 1.4%.

$AZN$CRNX$LLY$VERA$VRTX
Sectors

Sector Update: Healthcare

Healthcare stocks were higher late Tuesday afternoon, with the NYSE Healthcare Index rising 1.3% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 1.4%.The iShares Biotechnology ETF (IBB) climbed 1.2%.In corporate news, Vera Therapeutics' (VERA) Trutakna has been approved to reduce proteinuria in adults with primary immunoglobulin A nephropathy, the US Food and Drug Administration said in a Tuesday statement. Vera Therapeutics shares jumped past 7%.

$VERA
Insider Trading

Vera Therapeutics Insider Sold Shares Worth $701,769, According to a Recent SEC Filing

Marshall Fordyce, Director, President, and CEO, on June 23, 2026, sold 18,500 shares in Vera Therapeutics (VERA) for $701,769. Following the Form 4 filing with the SEC, Fordyce has control over a total of 420,274 Class A common shares of the company, with 198,244 shares held directly and 222,030 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1831828/000185945326000008/xslF345X05/form4-06242026_080643.xml

$VERA
Sectors

Sector Update: Healthcare Stocks Softer Late Afternoon

Healthcare stocks declined late Tuesday afternoon, with the NYSE Healthcare Index decreasing 0.8% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 0.9%.The iShares Biotechnology ETF (IBB) dropped 2.9%.In corporate news, Vera Therapeutics (VERA) said Tuesday it aligned with the US Food and Drug Administration on a revised analysis plan for its phase 3 Origin trial of atacicept in adults with IgA nephropathy. Its shares fell past 7%.Abivax (ABVX) faces an increasing risk of black box warning for obefazimod due to malignancies reported from a recent trial, Wedbush Securities said in a note. Abivax shares fell 43%.Heron Therapeutics (HRTX) shares dropped 42% after the company said the US District Court for the District of Delaware has ruled that claims in two of its Cinvanti injectable emulsion patents are invalid.Praxis Precision Medicines' (PRAX) shares lost 20% after it reported late Monday that its phase 2/3 trial assessing vormatrigine to treat focal onset seizures failed to meet its primary endpoint of percent change in monthly seizure frequency from baseline.

$ABVX$HRTX$PRAX$VERA
Sectors

Sector Update: Healthcare

Healthcare stocks declined late Tuesday afternoon, with the NYSE Healthcare Index decreasing 0.8% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 0.9%.The iShares Biotechnology ETF (IBB) dropped 2.9%.In corporate news, Vera Therapeutics (VERA) said Tuesday it aligned with the US Food and Drug Administration on a revised analysis plan for its phase 3 Origin trial of atacicept in adults with IgA nephropathy. Its shares fell past 6%.

$VERA
Wire

Vera Therapeutics Aligns With FDA on Earlier Atacicept Analysis to Support Potential Full Approval

Vera Therapeutics (VERA) said Tuesday it aligned with the US Food and Drug Administration on a revised analysis plan for its phase 3 Origin trial of atacicept in adults with IgA nephropathy.The biotechnology company said estimated glomerular filtration rate results from the trial are now expected in Q3. Pending those results, Vera plans to submit a supplemental biologics license application for full approval in Q4.Vera said the FDA alignment was supported by phase 2b Origin trial results showing significant reductions in proteinuria, stabilization of kidney function and a placebo-comparable safety profile, while its phase 3 Origin trial met its primary endpoint and remains ongoing to evaluate eGFR changes.Atacicept has received FDA Breakthrough Therapy Designation for IgAN, and Vera is also studying the drug in other kidney diseases, with enrollment completed in a separate dose-ranging study, the company said.Shares of Vera Therapeutics were down more than 6% in Tuesday trading.Price: $31.76, Change: $-2.18, Percent Change: -6.42%

$VERA
Insider Trading

Vera Therapeutics Insider Sold Shares Worth $1,011,051, According to a Recent SEC Filing

Marshall Fordyce, Director, President, and CEO, on April 14, 2026, sold 22,951 shares in Vera Therapeutics (VERA) for $1,011,051. Following the Form 4 filing with the SEC, Fordyce has control over a total of 457,274 Class A common shares of the company, with 235,244 shares held directly and 222,030 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1831828/000185945326000006/xslF345X05/form4-04152026_080434.xml

$VERA

Track with the FINWIRES app suite

FolioX
FolioX
Track VERA in your portfolio
WheelAI
WheelAI
Analyze VERA options with the wheel strategy
StockInsider
StockInsider
See market sentiment on VERA